Admera Health’s Clinical Offering Grows With PGxOne Plus and OncoGxOne

SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--Molecular diagnostics company, Admera Health, today announced PGxOne™ Plus and OncoGxOne™ have been approved for clinical use by The New Jersey Department of Health.

“OncoGxOne™ enables the detection of all types of genetic variations with great sensitivity and accuracy, including point mutations, indels, gene fusions, and copy number variance”

Enriching the company’s robust pipeline of products spanning the continuum of care, PGxOne™ Plus and OncoGxOne™ both utilize cutting-edge next generation sequencing technologies and advanced bioinformatics analysis. The medically actionable data delivered from these tests enable physicians to provide more personalized, precise treatment plans for their patients.

PGxOne™ Plus is an expanded version of PGxOne™, a proprietary pharmacogenomics test that helps predict patient responses to drug therapy based on their individual genetic makeup. The enhanced panel assays 25 well-established pharmacogenomics genes, thus facilitating more effective treatment planning across multiple therapeutic areas.

OncoGxOne™ detects all currently known, clinically relevant genetic alterations in cancer genes. The test provides clear, concise, medically actionable recommendations for targeted therapy as well as chemotherapy.

“OncoGxOne™ enables the detection of all types of genetic variations with great sensitivity and accuracy, including point mutations, indels, gene fusions, and copy number variance,” stated Dr. Guanghui Hu, President, Admera Health. “The comprehensive results from both OncoGxOne™ and PGxOne™ Plus offer cost-effective, clinically relevant data to guide physicians’ decisions for improved patient care.”

Hu continued, “With the approval of both tests, we have the opportunity to not only transform the treatment of cancer and other major diseases, but also advance the field of precision medicine, delivering transformative solutions for patients, physicians, and payers.”

Focusing on the development of products that improve patient health and well-being through the direct delivery of personalized, medically actionable results, the Admera Health pipeline includes non-invasive cancer testing, inherited cardiovascular disease testing, and disease focused panels.

About Admera Health

Admera Health is a molecular diagnostics company focused on personalized medicine. Utilizing advanced genomic technologies and bioinformatics analysis, Admera Health delivers cost-effective clinical diagnostics spanning the continuum of care from its established, CLIA-certified, CAP-accredited laboratory. Admera Health is a GENEWIZ company. For more information, please visit www.admerahealth.com.